This month, a number of Australia's most popular shares have released updates.
Brokers have had time to review these updates and give their verdict. So, have they named them as buys, holds, or sells? Let's find out:
Image source: Getty Images
Commonwealth Bank of Australia (ASX: CBA)
Morgans notes that Australia's largest bank underperformed expectations in the third quarter.
Combined with a challenging outlook and the tightening of its balance sheet, the broker has reaffirmed its sell rating with a trimmed price target of $119.40. It said:
3Q26 earnings were below 1H26 growth expectations, both before and after the impact of topping up loan loss provisions. The balance sheet as per the CET1 capital ratio also looks a little tighter than we had previously budgeted. FY26-28 EPS forecasts downgraded c.3-5%. Target price reduced 4% to $119.40. SELL retained, with potential total return of c.-19% at current prices (including c.3.3% dividend yield). Even after today's c.10% sell-off, CBA's valuation metrics remain extended and don't provide a sufficient margin of safety.
CSL Ltd (ASX: CSL)
Morgans was disappointed with CSL's guidance downgrade last week.
However, it remains upbeat and believes the issues the company is facing are temporary and not structural.
As a result, with CSL shares down heavily, Morgans has named them as a buy with a $147.59 price target. Commenting on the biotech giant, the broker said:
FY26 guidance was downgraded on China Albumin price pressure, US Ig channel inventory normalisation and other impacts (paused Iran sales, lower Hemgenix and and Iron sales), combined with a further cUS$5bn in flagged impairments. Importantly, issues are framed as primarily executional rather than structural, with infrastructure overbuild, organisational complexity, and weak commercial execution cited, while underlying demand and industry structure remain healthy.
Encouragingly, Seqirus is performing better than expected, Ig demand remains mid-to-high single digit, and there are early signs of plasma share stabilisation. While forward earnings visibility remains limited, we believe the current valuation increasingly discounts a structurally impaired plasma franchise, which we do not believe the current industry dynamics support. We reduce FY26-28 forecasts and lower our blended DCF, PE and EV/EBITDA-based target price to A$147.59. Given CSL's global leadership positions, structurally growing end markets and operational initiatives, we retain a BUY rating.
Life360 Inc. (ASX: 360)
Bell Potter was pleased with this family safety and location technology company's first-quarter update.
It notes that Life360 outperformed expectations on everything but monthly active users (MAU), which missed due to a technical issue.
In response, the broker has put a buy rating and $32.50 price target on Life360's shares. It said:
1Q2026 revenue and adjusted EBITDA of US$143.1m and US$17.1m were 4% and 18% ahead of our forecasts and 4% and 14% ahead of VA consensus. The key positive of the result was the strong paying circle growth of 201k q-o-q which was more than double our forecast of 99k and well ahead of VA consensus of 109k.
